Status:
RECRUITING
Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding
Lead Sponsor:
Donald Arnold
Conditions:
Acute Leukemia
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will a...
Eligibility Criteria
Inclusion
- ≥18 years old.
- Inpatient
- Diagnosis of acute myeloid leukemia or acute lymphocytic leukemia.
- Less than 5 days have elapsed since the start of induction chemotherapy treatment.
- Hemoglobin at enrolment is under 130 g/L.
Exclusion
- Failure to provide informed consent.
- Unwilling to receive blood transfusions.
- Life expectancy \<72 hours.
- Undergoing palliative chemotherapy.
- Requires specialized blood products (e.g., antigen-matched, irradiation, etc.).
- Diagnosis of acute promyelocytic leukemia.
- Diagnosis of hyperleukocytosis (a white blood cell count exceeding 100 × 10\^9/L).
- Diagnosed with coagulopathies or ongoing treatment with therapeutic anticoagulants, aspirin or nonsteroidal anti-inflammatory drugs (history of inherited or acquired coagulation disorder, known hemolytic disease, INR \> 1.5)
- Evidence of iron overload (ferritin \>800 ng/mL, transferrin saturation \>80%) .
Key Trial Info
Start Date :
April 11 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06947044
Start Date
April 11 2025
End Date
November 1 2026
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Juravinski Hospital
Hamilton, Ontario, Canada, L8V 1C3